# T030 (belotecan derivative)

Source: https://onco.cc/terms/t030/  
OnCo record `t030` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

T030 is the belotecan-derived topoisomerase payload in sacituzumab tirumotecan, designed to be less affected by the pumps that eject SN-38.

## Summary

T030 is a camptothecin analogue derived from belotecan. Kelun and MSD report weaker efflux-pump susceptibility than SN-38 and a more stable linker, which may translate into a different resistance and toxicity profile within the same mechanistic class. Evidence comes largely from sponsor data and Chinese trials, so treat cross-class comparisons as provisional.

## Fields

- Kind: Term
- Last checked: 2026-09-09
- Also known as: KL610023 payload; belotecan derivative; belotecan derivatives; KL610023

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Belotecan
- Wikipedia: https://en.wikipedia.org/wiki/Belotecan

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- terms: [Drug efflux pumps (ABC transporters)](https://onco.cc/terms/efflux-pump/), [Payload (ADC)](https://onco.cc/terms/payload/), [Topoisomerase-I inhibitor payloads](https://onco.cc/terms/topoisomerase-i-payloads/)
- drugs: [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)

---
JSON: https://onco.cc/api/v1/entities/t030.json